Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + etoposide + atezolizumab in elderly patients with extensive-stage small-cell lung cancer
jRCTs041210002Phase 2Completed
- Start
- Sep 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, etoposide and atezolizumab in small cell lung cancer (SCLC). Primary endpoint: 12-month overall survival rate. Started Sep 2021; status: completed.
02
Drugs
carboplatinetoposideatezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCTs041210002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210002.